Empagliflozin 25 mg Tablets

1. What is Empagliflozin?

Empagliflozin is an oral medication from the drug class SGLT2 inhibitors (Sodium–Glucose Co-Transporter-2 inhibitors).

Purpose

• Primarily used to improve blood glucose control in adults with Type 2 Diabetes Mellitus (T2DM).
• Also used to reduce cardiovascular death in adults with T2DM and established heart disease.
• Helps in heart failure (HFrEF and HFpEF) to reduce hospitalizations.
• Provides renal (kidney) protection by slowing disease progression.

2. How Empagliflozin Works (Mechanism of Action)

• In kidneys, SGLT2 proteins reabsorb glucose back into the bloodstream.
• Empagliflozin blocks SGLT2, causing:
  • Excess glucose to be excreted in urine
  • Reduced blood sugar levels independently of insulin
  • Mild caloric loss (≈200–300 kcal/day)
  • Increased sodium excretion → reduces blood pressure

Key Effects

• Lowers fasting and post-meal blood glucose
• Slight weight reduction
• Mild blood pressure reduction
• Cardiovascular and renal protective effects

3. Available Strengths

Empagliflozin tablets generally come in:

• 10 mg
• 25 mg (your query)

25 mg dose is often used when:

• 10 mg isn’t giving adequate response
• Heart failure or kidney protection benefits are desired

4. Appearance & Composition

Empagliflozin 25 mg tablet (varies by brand):

• Usually white to off-white, round/oval, film-coated tablet.
• Contains:
  • Active ingredient: Empagliflozin 25 mg
  • Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, hydroxypropyl cellulose, etc. (varies).

5. Uses (Indications)

A. Type 2 Diabetes Mellitus

• Used alone (monotherapy) or with other anti-diabetic drugs such as:
  • Metformin
  • DPP-4 inhibitors
  • Insulin
  • GLP-1 receptor agonists

B. Heart Failure

• Reduces risk of:
  • Hospitalization for heart failure
  • Cardiovascular death

C. Chronic Kidney Disease (CKD)

• Slows kidney function decline.
• Reduces risk of kidney failure progression.

6. Benefits

• Lowers HbA1c by 0.7–1.0%
• Weight loss of 2–3 kg on average
• Low risk of hypoglycemia (unless used with insulin or sulfonylurea)
• Decreases systolic BP by 3–5 mmHg
• Cardiovascular mortality reduction
• Kidney protection independent of glucose control

7. Pharmacokinetics (Technical Details)

Property	Detail
Absorption	Rapid; peak in 1.5 hrs
Bioavailability	~75%
Half-life	12–13 hours
Metabolism	Minor – mainly glucuronidation
Excretion	Urine + feces
Protein binding	86%

8. How to Take It

• Taken once daily, with or without food.
• Usually swallowed whole with water.
• Can be taken any time of day.

(Dosing schedules must be advised by a clinician — not provided here.)

9. Who SHOULD NOT Take It (Contraindications)

• Type 1 diabetes (risk of diabetic ketoacidosis)
• Patients on dialysis
• Severe kidney impairment (eGFR cutoffs vary by guideline)
• History of severe hypersensitivity to empagliflozin

10. Possible Side Effects

Common

• Increased urination
• Genital yeast infections (men & women)
• Urinary tract infections
• Thirst
• Dehydration symptoms
• Mild drop in blood pressure
• Weight loss

Less Common

• Increased LDL cholesterol
• Dizziness due to fluid loss

Rare but Serious

• Euglycemic diabetic ketoacidosis (EDKA)
• Necrotizing fasciitis of perineum (Fournier’s gangrene) – very rare
• Severe dehydration leading to kidney impairment

11. Drug Interactions

Be cautious with:

• Diuretics → increases dehydration/hypotension
• Insulin or sulfonylureas → risk of hypoglycemia
• RAAS blockers (ACE/ARB) → monitor kidney function
• Lithium (may alter levels)

12. Special Precautions

• Maintain sufficient hydration
• Monitor kidney function (eGFR)
• Monitor for signs of ketoacidosis: nausea, abdominal pain, rapid breathing
• Good genital hygiene to reduce yeast infection risk
• Stop before major surgery or prolonged fasting

13. Brands (India Examples)

• Jardiance (Original – Boehringer Ingelheim)
• Empa, Glyflozin, Epanorm, Emflo, Empaglow, etc.

For related options on EasyRxDrug, readers can browse the online pharmacy product catalog. For additional general safety context, review NIDDK diabetes information. This information is educational only and does not replace advice from a licensed clinician or pharmacist.